Search results for "sodium-glucose co-transporter-2 inhibitor"

showing 2 items of 2 documents

The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics

2020

Abstract Background The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD; NCT03036150) trial was designed to assess the effect of the sodium–glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin on kidney and cardiovascular events in participants with CKD with and without type 2 diabetes (T2D). This analysis reports the baseline characteristics of those recruited, comparing them with those enrolled in other trials. Methods In DAPA-CKD, 4304 participants with a urinary albumin:creatinine ratio (UACR) ≥200 mg/g and estimated glomerular filtration rate (eGFR) between 25 and 75 mL/min/1.73 m2 were randomized to dapagliflozin 10 mg once daily or placebo. Me…

MaleIGA NEPHROPATHYRATIONALEPROGRESSIONType 2 diabetesurologic and male genital diseasesDiabetic nephropathychemistry.chemical_compoundGlucosidesDESIGNMedicineFAILUREDiabetic NephropathiesDapagliflozinrandomized controlled clinical trialPrognosisfemale genital diseases and pregnancy complications//purl.org/pe-repo/ocde/ford#3.02.13 [https]Cardiovascular DiseasesNephrologyFemalesodium–glucose co-transporter-2 inhibitormedicine.symptomBENAZEPRILGlomerular Filtration Ratemedicine.medical_specialtyFinerenoneINHIBITIONNephropathy//purl.org/pe-repo/ocde/ford#3.02.20 [https]Double-Blind MethodClinical ResearchInternal medicineDiabetes mellitusEND-POINTSHumansBenzhydryl CompoundsRenal Insufficiency ChronicAcademicSubjects/MED00340Sodium-Glucose Transporter 2 InhibitorsAgedTransplantationDECLINEbusiness.industrysodium-glucose co-transporter-2 inhibitordapagliflozinmedicine.diseaseEFFICACYEditor's ChoiceDiabetes Mellitus Type 2chemistryAlbuminuriaORIGINAL ARTICLESbusinesschronic kidney diseaseKidney disease
researchProduct

Empagliflozin Induces White Adipocyte Browning and Modulates Mitochondrial Dynamics in KK Cg-Ay/J Mice and Mouse Adipocytes

2021

Background: White adipose tissue (WAT) browning is a promising target for obesity prevention and treatment. Empagliflozin has emerged as an agent with weight-loss potential in clinical and in vivo studies, but the mechanisms underlying its effect are not fully understood. Here, we investigated whether empagliflozin could induce WAT browning and mitochondrial alterations in KK Cg-Ay/J (KKAy) mice, and explored the mechanisms of its effects.Methods: Eight-week-old male KKAy mice were administered empagliflozin or saline for 8 weeks and compared with control C57BL/6J mice. Mature 3T3-L1 adipocytes were treated in the presence or absence of empagliflozin. Mitochondrial biosynthesis, dynamics, a…

browningmedicine.medical_specialtyfusionChemistrytype 2 diabetes mellitusPhysiologyMFN2AMPKsodium-glucose co-transporter-2 inhibitorWhite adipose tissueMitochondrionThermogeninmitochondrial dynamicsmitochondriamedicine.anatomical_structureEndocrinologyMitochondrial biogenesisPhysiology (medical)Internal medicineBrown adipose tissueEmpagliflozinmedicineQP1-981Original ResearchFrontiers in Physiology
researchProduct